	U.S. Patent and Trademark  TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING  REJECTION OVER A PENDING SECOND APPLICATION  In re Application of: Gregory R. MUNDY et al.  Application No.: 09/695,807  Filed: October 23, 2000  For: INHIBITORS OF PROTEASOMAL ACTIVITY FOR STIMULATING BO  The owner, OsteoScreen Inc.  percent Interest in the Instant application hereby disclaims, except as provided below, the terminal part of an application Number (09/254,973), filed on 10/29/1999 and 4/25/2000  Ending second Application Number (09/255,973), filed on 10/29/1999 and 4/25/2000  Control only on the instant application in the instant application. The owner hereby agrees that any patent so granted on the instant application in the instant application in the instant application and is bridged upon the agreement runs with any patent granted on the instant application and is bridging upon the application in the above disclaimer, the owner does not disclaim the terminal part of any application that would extend to the expiration date of the full statutory term as defined in 25 to application that would extend to the expiration date of the full statutory term as defined in 25 to application that would extend to the expiration date of the full statutory term as defined in 25 to application that would extend to the expiration date of the full statutory term as defined in 25 to application that would extend to the expiration date of the full statutory term as defined in 25 to application that would extend to the expiration date of the full statutory term as defined in 25 to application that would extend to the expiration date of the full statutory term as defined in 25 to application that would extend to the expiration date of the full statutory term as defined in 25 to application that would extend to the expiration date of the full	Docket Number (Optional) 432722002623  ONE GROWTH (AS  of 100%  nal part of the statutory term of the full statutory term defined my patent granted on pending  of any patent on the instant application shall be like transported on the grantee. Its successory or
	Application No.: 09/695,807  Filed: October 23, 2000  INHIBITORS OF PROTEASOMAL ACTIVITY FOR STIMULATING BO AMENDED)  The owner, OsteoScreen Inc. percent Interest in the Instant application hereby disclaims, except as provided below, the terminal patent granted on the Instant application, which would extend beyond the expiration date of in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of a certain second Application Number (09/556,973), filed on (10/29/1996 and 4/25/2000 pending second application. The owner hereby agrees that any patent so granted on the instant expedication and is binding upon its land any patent granted on the instant explication and is binding upon its landary the above steakelesses the control on the instant explication and is binding upon its landary the above steakelesses the control on the instant explication and is binding upon its landary the above steakelesses the control on the instant explication and is binding upon its landary the above steakelesses the control of the c	one granted on pending  of any patent on the instant application shall be like time and application are commonly owned, the grantee, its successors or
	Filed: October 23, 2000  INHIBITORS OF PROTEASOMAL ACTIVITY FOR STIMULATING BOAMENDED)  The owner*, OsteoScreen Inc. percent Interest in the Instant application hereby disclaims, except as provided below, the terminary patent granted on the Instant application, which would extend beyond the expiration date of in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of a second Application Number Ocies, e73, filed on 10/28/1998 and 4/25/2000 pending second application. The owner hereby agrees that any patent so granted on the instant experience on the second application and is binding upon the segment runs with any patent granted on the instant explication and is binding upon the limitant of the shorter disclaims the second application and is binding upon the limitant optication and is binding upon the limitant opt	. of 100%  mal part of the statutory term of f the full statutory term defined my patent granted on pending  , of any patent on the instant application shall be literature are commonly owned, the grantee, its successors or
	For: INHIBITORS OF PROTEASOMAL ACTIVITY FOR STIMULATING BOAMENDED)  The owner*, OsteoScreen Inc.  percent interest in the instant application hereby disclaims, except as provided below, the termis any patent granted on the instant application, which would extend beyond the expiration date or in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of a second Application Number 09/25,973 , filed on 10/29/1999 and 4/25/2000 pending second application. The owner hereby agrees that any patent so granted on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the second application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and is binding upon its land on the instant application and its land on t	. of 100%  mal part of the statutory term of f the full statutory term defined my patent granted on pending  , of any patent on the instant application shall be literature are commonly owned, the grantee, its successors or
	The owner*, OsteoScreen Inc.  percent Interest in the instant application hereby disclaims, except as provided below, the terminal patent granted on the instant application, which would extend beyond the expiration date of a 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of a country of the grant of a country of the percent of the prior to the grant of a country of the second application. The owner hereby agrees that any patent so granted on the prior to the granted on the second application and its binding upon the second application and its binding upon the prior the above stable as the country of the second application and its binding upon the percent of the second application and its binding upon the percent of the second application and its binding upon the percent of the second application and its binding upon the second application and its bin	. of 100%  mal part of the statutory term of f the full statutory term defined my patent granted on pending  , of any patent on the instant application shall be literature are commonly owned, the grantee, its successors or
	percent Interest in the instant application hereby disclaims, except as provided below, the terminary patent granted on the instant application, which would extend beyond the expiration date or in 35 U.S.C. 154 and 173 as shortened by any terminal disclaimer filed prior to the grant of a second Application Number 69/55,973 , filed on 10/29/1999 and 4/25/2000 pending second application. The owner hereby agrees that any patent so granted on the instant application and is binding upon the instant application and its binding upon the	r the full statutory term defined my patent granted on pending , of any patent on the s instant application shall be lication are commonly owned, the grantee, its successory or
C 1	premised on the second application, as shortened by any terminal disclaimer filed prior to the pate such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is competent jurisdiction, is statutority disclaimed in whole or terminally disclaimed under 37 CFR to the expiration certificate, is reissued, or is in any manner terminated prior to the expiration that there is no superior to the expiration of the patents of the competent prior to the expiration of the competent prior to the expiration of the competent prior to the expiration of the undersigned is empowered to act on behalf of the organization.  I hereby declare that all statements made herein of my own knowledge are true and information and belief are believed to be true; and further that these statements were made we say the statements and the like or made or made we have the like a made the like or made we have the statements and the like or made we have that these statements were made we have the like or made we have the like or made or made or made or made or made or made we have the like or made or ma	that all statements made on the knowledge of the knowledg
th	nited States Code and that such willful false statements may jeopardize the validity of the appearence.	ection 1001 of Title 18 of the fication or any patent Issued
	The undersigned is an attorney or agent of record.  Fall & Muse Signature	7(2c/04
	Kate H. Murashige - 2	29,959
'27/2004 GTRAHMEI	Typed or printed ner 00000009 031952 09695807 (858) 720-5112	
FC:2814	Telephone Number X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assign Form PTO/S8/96 may be used for making this statement. See MPEP § 324.	ee (owner).

sd-209026

PAGE 5/5 \* RCVD AT 7/21/2004 6:30:06 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-1/6 \* DNIS:8729306 \* CSID:18587205125 \* DURATION (mm-ss):01-44